Pharmaceutical News

RSS

Peregrine licenses worldwide rights to a novel anti-angiogenesis technology

Peregrine Pharmaceuticals, Inc. has announced that it has licensed worldwide exclusive rights to a novel anti-angiogenesis technology from The University of Texas M. D. Anderson Cancer Center.

10 Jul 2007

Novavax licenses virus-like particle from Wyeth

Novavax, Inc. has announced that is has signed a non-exclusive, worldwide license agreement with Wyeth, to obtain rights to a patent application covering virus-like particle (VLP) technology for use in human vaccines in certain fields of use.

10 Jul 2007

MacroGenics investigational new drug for West Nile vrus monoclonal antibody is active

MacroGenics has announced that the company's investigational new drug (IND) application to the U.S. Food and Drug Administration for its monoclonal antibody targeted to West Nile Virus is now active.

10 Jul 2007

Bio-adhesive vaginal foam

Foamix Ltd. has announced that the Company has been selected to present at the 34th Annual Meeting of the Controlled Release Society.

10 Jul 2007

Calypte begins U.S. initiative

Calypte Biomedical Corporation has announced that it has leased an 11,000+ square foot site located in Portland, Oregon.

10 Jul 2007

Approval of generic Dostinex

Barr Pharmaceuticals, Inc. has announced that its subsidiary Barr Laboratories, Inc. has received final U.S. Food & Drug Administration (FDA) approval for its application to manufacture and market a generic version of Pharmacia and Upjohn Company's Dostinex (cabergoline) tablets, 0.5 mg.

10 Jul 2007

Actavis launches Terbinafine hydrochloride tablets in the U.S.

Actavis Group has announced that it has launched Terbinafine hydrochloride tablets in the U.S. Distribution of the product will commence immediately.

10 Jul 2007

FDA designates Carbaglu for treatment of NAGS deficiency as a Fast Track product

The Food and Drug Administration (FDA) in the USA has concluded that Carbaglu (carglumic acid) for treatment of N-acetylglutamate synthase (NAGS) deficiency meets the criteria for fast track designation.

10 Jul 2007

Drug costs cut in Norway following new rule on prescribing

Research in Norway has shown that there have been substantial savings in drug costs since the introduction of a regulation requiring doctors to prescribe the recommended first-line treatment for hypertension (high blood pressure).

9 Jul 2007

New skin patch offers help for Alzheimer's victims

The Food and Drug Administration (FDA) in the United States has given approval for the first skin patch to treat Alzheimer's disease.

9 Jul 2007

Roche and Alnylam form RNAi therapeutics alliance

Roche and the US-based biopharmaceutical company Alnylam Pharmaceuticals, Inc. announced today that they have entered into a major alliance in which Roche obtains a non-exclusive license to Alnylam's technology platform for developing RNAi (RNA interference) therapeutics.

9 Jul 2007

Barr to market generic LAMISIL tablets

Barr Pharmaceuticals has announced that Gedeon Richter, Plc. has received final U.S. Food & Drug Administration (FDA) approval for its application to manufacture and market a generic version of Novartis Pharmaceutical Corporation's LAMISIL (terbinafine hydrochloride) Tablets, 250 mg. The approval follows the expiration of pediatric exclusivity for LAMISIL.

4 Jul 2007

Alli jokes - great marketing!

GlaxoSmithKline's new diet drug, Alli, hit shelves nationwide last month.

4 Jul 2007

Tamiflu for children

The Food and Drug Administration (FDA) in the United States has given approval for Tamiflu to be used for children but at a lower dose than the adult version.

4 Jul 2007

Biomira files NDA for novel inhibitor of hypoxia-inducible factor-1 alpha

Biomira Inc. has announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for PX-478. PX-478 has been shown in preclinical studies to inhibit hypoxia-inducible factor (HIF)-1 alpha, a protein that controls the transcription of a number of genes whose products are important for tumor growth and survival.

4 Jul 2007

A view on new drugs for macular degeneration

Restricting use of drugs for macular degeneration to patients who have already gone blind in one eye is "unacceptable" concludes the July issue of Drug and Therapeutics Bulletin (DTB).

4 Jul 2007

DIY tooth whitening kits can be dangerous

Consumers in Britain are being warned that some DIY tooth whitening kits can be dangerous.

28 Jun 2007

FDA fast tracks ViroPharma's treatment of hepatitis C

ViroPharma has announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for HCV-796 for treatment of hepatitis C virus infection.

28 Jun 2007

Bayer and Onyx submit supplemental NDA for Nexavar

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals have announced that a Supplemental New Drug Application (sNDA) for Nexavar (sorafenib) tablets has been submitted to the U.S. Food and Drug Administration (FDA) for the treatment of patients with hepatocellular carcinoma (HCC), the most common form of liver cancer. Nexavar is currently approved in more than 50 countries for the treatment of advanced kidney cancer.

28 Jun 2007

Actavis launches Ondansetron tablets in the U.S.

Actavis Group has announced that it has launched Ondansetron Tablets in the U.S. Actavis will market the product under an agreement with Natco Pharma Limited. Distribution of the product will commence immediately.

28 Jun 2007